KOTAK ON EMCURE PHARMACEUTICALS ; BUY | TARGET ₹2,450

• Hikes FY27 revenue growth guidance to over 20% from mid-teens earlier. • Targets upper end of 75–100 BPS EBITDA margin expansion guidance. • Zuventus recovery, new product launches and deeper molecule penetration expected to accelerate domestic growth. • International business remains a key growth driver. • Kotak expects 19% EPS CAGR over FY26–29.

EMCURE PHARMACEUTICALS L

← Back to feed